Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

Phase 2

Recruiting

Conditions: Osteochondrodysplasia

Interventions: Drug: SAR442501

First Posted Date: 2023-10-04

Last Posted Date: 2024-11-20

Lead Sponsor: Sanofi

Target Recruit Count: 36

Registration Number: NCT06067425

Locations: 🇮🇹
Investigational Site Number : 3800002, Milan, Lombardia, Italy
🇦🇺
Investigational Site Number : 0360001, Parkville, Victoria, Australia
🇨🇳
Investigational Site Number : 1560002, Shanghai, China

and more 6 locations

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Tolebrutinib
Drug: gemfibrozil
Drug: rifampicin

First Posted Date: 2023-10-03

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi

Target Recruit Count: 30

Registration Number: NCT06064539

Locations: 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States

An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma

Completed

Conditions: Asthma

Interventions: Other: No intervention

First Posted Date: 2023-10-03

Last Posted Date: 2024-11-14

Lead Sponsor: Sanofi

Target Recruit Count: 144

Registration Number: NCT06064526

Locations: 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Completed

Conditions: Influenza Immunization (Healthy Volunteers)

Interventions: Biological: Quadrivalent Influenza Vaccine
Biological: High-Dose Quadrivalent Influenza Vaccine

First Posted Date: 2023-09-28

Last Posted Date: 2023-12-27

Lead Sponsor: Sanofi

Target Recruit Count: 2075

Registration Number: NCT06059456

Locations: 🇫🇮
Investigational Site Number : 2460001, Helsinki, Finland
🇩🇪
Investigational Site Number : 2760010, Martinsried, Germany
🇩🇪
Investigational Site Number : 2760003, Martinsried, Germany

and more 8 locations

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 2

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: SAR444656 (KT-474)
Drug: Placebo

First Posted Date: 2023-09-28

Last Posted Date: 2024-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 200

Registration Number: NCT06058156

Locations: 🇺🇸
University of Pittsburgh Medical Center Site Number: 8400006, Pittsburgh, Pennsylvania, United States
🇺🇸
Wayne Health-Dearborn Site Number: 8400009, Dearborn, Michigan, United States
🇺🇸
Encore Medical Research Site Number: 8400002, Boynton Beach, Florida, United States

and more 22 locations

Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

Recruiting

Conditions: Fabry Disease

First Posted Date: 2023-09-25

Last Posted Date: 2023-12-20

Lead Sponsor: Sanofi

Target Recruit Count: 100

Registration Number: NCT06052800

Locations: 🇨🇳
Investigational Site Number :1580001, Taipei, Taiwan
🇨🇳
Investigational Site Number :1580003, Taipei, Taiwan
🇨🇳
Investigational Site Number :1580002, Taipei, Taiwan

and more 2 locations

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2023-09-15

Last Posted Date: 2024-03-15

Lead Sponsor: Sanofi

Target Recruit Count: 900

Registration Number: NCT06039241

Locations: 🇩🇪
Investigational Site Number: 186, Karlsruhe, Germany
🇩🇪
Investigational Site Number: 069, Köln, Germany
🇩🇪
Investigational Site Number: 004, Berlin, Germany

and more 52 locations

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Amlitelimab
Drug: Placebo

First Posted Date: 2023-09-13

Last Posted Date: 2025-01-01

Lead Sponsor: Sanofi

Target Recruit Count: 380

Registration Number: NCT06033833

Locations: 🇯🇵
Investigational Site Number : 3920010, Sakai, Osaka, Japan
🇯🇵
Investigational Site Number : 3920004, Chuo, Tokyo, Japan
🇯🇵
Investigational Site Number : 3920019, Hiroshima, Japan

and more 64 locations

A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: SAR444656 (KT-474)
Drug: Placebo

First Posted Date: 2023-09-08

Last Posted Date: 2024-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 156

Registration Number: NCT06028230

Locations: 🇺🇸
Clear Dermatology & Aesthetics Center Scottsdale Site Number : 8400006, Scottsdale, Arizona, United States
🇺🇸
First OC Dermatology Site Number: 8400007, Fountain Valley, California, United States
🇺🇸
Encore Medical Research - Boyton Beach Site Number : 8400002, Boynton Beach, Florida, United States

and more 29 locations

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Phase 4

Recruiting

Conditions: Fabry's Disease

Interventions: Drug: AGALSIDASE BETA (GZ419828)
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Dexamethasone
Drug: Montelukast

First Posted Date: 2023-08-31

Last Posted Date: 2024-08-09

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT06019728

Locations: 🇺🇸
Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
🇺🇸
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002, Fairfax, Virginia, United States
🇺🇸
Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States

and more 2 locations

Home Terms & Conditions Privacy Policy